compounding semaglutide fda enforcement news today GLP-1 Medications – Guidance and Compounded Products FDA Targets GLP-1 and Peptide

requires continuous treatment adherence, logged weights in patient portal, and provider check-ins

Foundational work on Thymosin Beta-4

The four-day break allows the active metabolite to clear and gives hepatocytes a recovery window between cycles

The medication is technically only FDA approved to treat Type 2 diabetes, but its so effective at reducing body weight that healthcare providers often prescribe it off-label as a weight loss medication

On the flip side, we also have strong evidence that resistance training during caloric restriction helps preserve lean mass and strength, especially compared to dieting alone

In this study, we investigated these features using transomic analysis